Proteus 7 1 Licence Key Executive Insurance

About Proteus Digital Health Armed with more than 450 issued patents and led by some of the brightest minds in technology, pharmaceuticals and healthcare, we’ve invented Digital Medicine, a new category of pharmaceuticals that measures medication treatment effectiveness, helps physicians improve clinical outcomes and patients reach health goals. Together, with leading health systems and pharmaceutical companies, we’re bringing this new digital solution to healthcare providers, thereby increasing access to better insight, optimized therapies and lower costs. Andrew Thompson Co-Founder, CEO Andrew Thompson is Co-Founder, President and Chief Executive Officer of Proteus Digital Health. His vision for Digital Medicines is focused on expanding global access to care, dramatically increasing the value delivered by drugs, and creating a more sustainable model for innovation in pharmaceuticals that leverages the power of silicon, software and mobile devices. Thompson is a World Economic Forum Advisor, and a member of the selection committee for the World Economic ForumTechnology Pioneers. He also serves on the California Governor’s Health IT Security Advisory Board.

Proteus 7 1 Licence Key Executive Recruiting. 5/13/2017 0 Comments Exact name of Registrant as specified in its charter) ENGLAND AND WALES. Wikipedia:Mistagged unreferenced articles cleanup/2. Driving licence in Denmark; Drizzle; Drood. For society to grant us our. We are also working with Proteus Partners.

Passionate about bringing digital innovation to education, he is Co-Founder and Board Member of Summit Schools, a leading Charter School organization with an acclaimed track record and unique digital platform, featured in the Davis Guggenheim movie “Waiting for Superman”. He works in digital humanities innovation as a Member of the Stanford University Libraries Board and with Cambridge University. He is a Co-Founder of Parker Library Online – a leading destination for digital medieval studies. Thompson has been active as a venture capital investor and entrepreneur in Silicon Valley for 30 years, completing several Fortune 100 M&A transactions and IPOs, and is a named author on 51 issued patents. He holds master’s degrees in Engineering (Cambridge), Education (Stanford) and Business (Stanford GSB). George Savage, M.D. Co-Founder, Chief Medical Officer George Savage is chief medical officer and co-founder of Proteus Digital Health, and formerly the company’s vice president of research and development.

He sees Digital Medicine as an invaluable collaboration platform for patient and physician, integrating information about a patient’s response to therapy directly into everyday healthcare. George is focused on developing the clinical and economic evidence needed to secure global regulatory approvals and spur widespread adoption of Proteus’s ingestible sensor platform. He serves on the board of the California Life Sciences Association, the Boston University College of Engineering advisory council, and in 2016 was elected a Fellow of the American Institute for Medical and Biological Engineering. George holds a B.S.

In biomedical engineering from Boston University, an M.D. From Tufts University School of Medicine, and an M.B.A. From Stanford University Graduate School of Business. He completed postgraduate training in surgery at the University of Massachusetts and is licensed to practice medicine in California. George has a successful 27-year track record of starting and developing technology-based healthcare companies in Silicon Valley. Mark Zdeblick, Ph.D.

Co-Founder, Chief Technologist Mark Zdeblick is chief technologist and co-founder of Proteus Digital Health, and leads the group innovating on our technology. Previously, Mark served as the chief technology officer for the optical switch group at K2 Optronics and served as founder and chief technology officer of Redwood Microsystems. Mark holds a B.S. In civil engineering and a B.A. In architecture, both from the University of Illinois, and an M.S. In aeronautics and astronautics and Ph.D.

In electrical engineering from Stanford University. Uneek Mehra Chief Financial Officer As Chief Financial Officer, Uneek is responsible for accounting, financial reporting, budgeting, business planning and forecasting.

He is also responsible for the Facilities, IT and People teams. Prior to joining Proteus, Uneek had extensive experience in senior finance leadership roles with Novartis, IBM and Citibank.

At Novartis, Uneek worked in roles with increasing responsibilities in the Corporate Finance, Commercial Finance, Corporate Business Development and Treasury departments across the US, Switzerland and China. He also served as CFO of two of the largest specialty Medicines Franchises within the Novartis US business. Uneek has a MBA in strategy and leadership from IMD, Lausanne, Switzerland as well as a Masters in Finance and a Bachelors in Engineering from premier universities in India. David O'Reilly Chief Platform Officer David O’Reilly is chief platform officer of Proteus Digital Health and leads the company’s Digital Medicine development, manufacturing, corporate development and corporate strategy areas. Prior to joining Proteus, David spent over 15 years starting and building life sciences companies focused on novel platforms for drug discovery and personalized medicine. He was President of Catalyst Biosciences, Chief Business Officer and member of the founding management team at Iconix Biosciences, and Head of Corporate Development for ARIAD Pharmaceuticals (where he was also the general manager of a subsidiary company, ARIAD Gene Therapeutics).

He began his career as a management consultant to health care and biotechnology companies at L.E.K. David is a graduate of Wesleyan University, where he was named the Gilbert Clee Scholar, and Harvard Business School, where he received an MBA with Distinction. Sean Handel Senior Vice President Product Sean Handel leads product management, design and software engineering at Proteus Digital Health. Most recently, Sean was Senior Vice President of Product at Swrve, a mobile engagement platform that helps major brands to engage their customers via their mobile apps. Previously, Sean was SVP Product Management and Marketing at Epocrates where he lead product initiatives from an early stage through the company’s IPO and subsequent acquisition by athenahealth. This included offerings for providers, health systems, health plans, and pharmaceutical companies. Epocrates became the number one brand in healthcare technology for physicians—at its peak, Epocrates was used by more than 50% of all physicians in the US and 1.4 million healthcare providers overall.

Sean holds Bachelor of Arts and Master of Science degrees in Computer Science from Northwestern University. He also advises technology startups in the healthcare technology and sports & fitness wearables areas.

Neela Paykel Head of Legal Affairs and Compliance Neela Paykel is head of legal affairs and compliance at Proteus Digital Health. Prior to joining Proteus, Neela was assistant general counsel and practice group leader at Genentech where she served as the lead attorney providing legal support to the managed markets business unit. She advised on a broad range of managed care, healthcare law, privacy, antitrust and FDA promotional issues.

Prior to Genentech, Neela was at CVS Caremark serving as the lead counsel for health plan PBM business and was an Associate Counsel at Blue Shield. Neela is a graduate of Illinois Wesleyan University with a Bachelor of Arts in International Business Administration and received her Juris Doctorate degree from George Washington University. Jonathan Symonds, CBE Chairman Jon Symonds, CBE, is Chairman of HSBC Bank Plc, Chairman of the Supervisory Board of Innocoll AG and Non-Executive Director of Genomics England. He serves on the boards of Tala Energy, Feliz Pharmaceuticals, Aetion Inc., and Mesoblast.

Formerly, Symonds was Chief Financial Officer of Novartis, Partner and Managing Director of Goldman Sachs and Chief Financial Officer of AstraZeneca Plc. Symonds has served on the Proteus Board of Directors since June of 2014 and now advises Proteus on strategy, financial management and corporate governance in his role as Chairman. Shumeet Banerji, Ph.D.

Board Member Shumeet Banerji is founder and partner of Condorcet, LP an investment and advisory firm. Banerji retired from Booz & Company Inc. Having served as its founding Chief Executive Officer. Formerly, he held leadership roles at Booz, Allen & Hamilton in India, the U.K., Europe and globally. He serves on the Board of HP, Inc., Reliance Industries Limited, Proteus Digital Health, Inc., Felix Pharmaceuticals Private Limited, and Tala Energy Private Limited.

Banerji provides oversight on Proteus’ corporate strategy and operational performance, among other topics of critical importance. Regina Benjamin, MD, MBA Board Member Dr.

Regina Benjamin is the Founder and CEO of BayouClinic in Bayou La Batre, Alabama, and the NOLA.com/Times Picayune Endowed Chair of Public Health Sciences at Xavier University of Louisiana. She was the 18 th United States Surgeon General (2009 – 2013).

Benjamin serves on the boards of Kaiser Foundation Health Plan and Hospitals, the largest U.S. Health managed care organization, and of Ascension, the world’s largest faith-based health system. She also serves on the boards of Diplomat, ConvaTec, CPSI, Next Level Health, and 98point6. Robert Epstein, M.D., M.S.

Board Member Dr. Robert Epstein is the cofounder and CEO of Epstein Health, LLC, a life science strategic consulting firm serving clients in the United States and Europe. Previously, Dr. Epstein served as president of the Medco-UBC Division and chief R&D officer of Medco Health Solutions, Inc. Epstein is the former president of the International Society of Pharmacoeconomics and Outcomes Research, and currently serves on the board of directors of Illumina, Fate Therapeutics, Veracyte, and Mindstrong Health. He has published more than 50 peer-reviewed medical articles and book chapters, and serves as a reviewer for several influential medical journals.

Frank Fischer Board Member Frank Fischer has more than 25 years of senior management experience in the medical device industry. The president and CEO of the biomedical device company NeuroPace, he has served on the company’s board since 1998 and joined the company as its chief executive officer in January 2000. Fischer continues to serve on the boards of several privately held medical device companies, in addition to serving on the board of trustees of Epilepsy Foundation of America, Rensselaer Polytechnic Institute, and Babson College. Swedish Board Member Joseph R.

SuperSpeed RamDisk Plus Desktop Free Download Latest Version for Windows. It is full offline installer standalone setup of SuperSpeed RamDisk Plus Desktop. Please input captcha to take your serial number. View in text. Similar activation keys. SuperSpeed RamDisk Plus v9.0.3.0. SuperSpeed offers two high-performance RAM disk products: RamDisk and RamDisk Plus® (compare). These products create virtual disks from the server's system memory (RAM). Although in many respects a virtual disk behaves like a physical hard disk, in one key area it does not: it is much, much faster, up to 50x faster or more. Superspeed ramdisk plus v10.0.1. RamDisk Plus adds multiple disk support, system page file support for HDD, and a versatile disk image backup and restore facility. You can manually save the RAM disk’s contents to an image file, or have the contents saved automatically when the computer is shutdown.

Swedish is Executive Chairman of Anthem Inc., a Fortune 50 company, and the nation’s leading health benefits provider. Formerly, Swedish served as CEO for several major integrated healthcare delivery systems, including Trinity Health, Colorado’s Centura Health, and Hospital Corporation of America. Swedish serves on numerous corporate and industry association boards, and joined the Proteus Board of Directors in February 2018. He received his bachelor’s degree from the University of North Carolina at Charlotte and his master’s degree in health administration from Duke University.

Work for a leader that's transforming the industry. We are Proteus Digital Health, the driving force behind an entirely new category of pharmaceuticals called Digital Medicine. Every day, our employees are blazing new trails at the intersection of pharmaceuticals, technology, software and healthcare. Our company is on the forefront of transformative change to the healthcare industry. We are searching for pioneers, problem-solvers and inquisitive minds to help realize our vision: to improve healthcare for everyone, everywhere. Do you want to work in a dynamic environment where you can grow personally as well as professionally?

Then apply today to join the Proteus team. 'We are developing a product that is changing people's lives.' Jeff Wiley, Head of Product Management At Proteus Digital Health, we are developing leading-edge technology that will revolutionize how healthcare is delivered. What does that mean for our associates?

They are playing an active role in the evolution of modern healthcare. Whether you are a software engineer, a data analyst or a pharmaceutical expert, you can help develop and deliver solutions that enhance the quality of care for everyone:. Patients get back on track. Physicians get deeper insight into patient health.

Healthcare systems can better measure, manage and improve the health of entire patient populations. “We acknowledge hard work and celebrate success every chance we get.” Priya Raval, Senior Designer, HFE and User Research. Proteus Digital Health is a company like no other, offering the discipline of a healthcare leader and the mentality of a tech innovator. Every week, our associates are taking on challenges and solving problems. As a company on the leading edge, we’re searching for a unique type of employee — someone with an entrepreneurial mindset and a can-do spirit who enjoys working in a fast-paced environment.

We offer:. Personal development — there’s always an opportunity to learn and grow. Entrepreneurial spirit — as an industry pioneer, we are constantly paving new ground.

Biegacze

Team mentality — we promote a culture of collaboration and teamwork. Dynamic working environment — every day is filled with new challenges and breakthroughs. Integrating Silicon with Drugs: Pushing the Boundaries of Pharma Manufacturing with Digital Medicines Time:Wednesday, September 19, 2018 Location:One Farrer Hotel & Spa, Singapore Speaker: Nik Leist, Senior Director, Ingestible Sensor Manufacturing/Site Leader The convergence of digital technologies with healthcare has led to significant changes in the way patients interact with their own health.

With greater access to mobile applications and wearable devices, patients are responding and engaging with their medications in ways never seen before. Despite these advancements, there continues to be a lack of insight into two of the most basic questions in healthcare: did the patient take their medication, and did the medication work? Digital Medicines is a new category of pharmaceuticals pushing the boundaries of Digital Health to answer these questions with a completely unique concept: the integration of technology directly into medications. From customizing machinery to partnering with global pharmaceutical companies, Nik Leist from Proteus Digital Health will walk through the steps it takes to develop a new category using medications with sensors, thus opening the door for more informed decisions and conversations across the healthcare landscape. Otsuka Otsuka and Proteus have combined Otsuka’s ABILIFY ® (aripiprazole) with the FDA-cleared Proteus ® ingestible sensor, embedding the sensor in single tablets at point of manufacture. The FDA granted its first approval of a Digital Medicine, ABILIFY MYCITE ® (aripiprazole tablets with sensor), on November 13, 2017. ABILIFY MYCITE ® is a drug -device combination product of Otsuka’s aripiprazole, an atypical antipsychotic, embedded with Proteus’ ingestible sensor that communicates with Proteus’ wearable sensor patch, and a smartphone application.

The product measures ingestion of ABILIFY MYCITE ® and patient activity, rest and mood. Otsuka’s first Digital Medicine provides an objective measure of medication-taking patterns of ABILIFY MYCITE ® to help enhance collaboration with healthcare providers, who treat patients with certain serious mental illnesses.

F-1 As filed with the Securities and Exchange Commission on September 1, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NUCANA PLC (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) England and Wales (State or other jurisdiction of incorporation or organization) 2834 (Primary Standard Industrial Classification Code Number) Not Applicable (I.R.S. Employer Identification Number) NuCana plc 10 Lochside Place Edinburgh, EH12 9RG United Kingdom Telephone: +44 (0)131 248 3660 (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices) Corporation Service Company 251 Little Falls Drive Wilmington, DE 19808 United States Telephone: +1 302 636 5400 (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service) Copies to: William C. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. One Financial Center Boston, MA 02111 Telephone: +1 617 542 6000 Facsimile: +1 617 542 2241 Hugh S.

Griffith Chief Executive Officer NuCana plc 10 Lochside Place Edinburgh, EH12 9RG United Kingdom Telephone: +44 (0)131 248 3660 Divakar Gupta, Esq. Brookshire, Esq. Cooley LLP 1114 Avenue of the Americas New York, NY 10036 Telephone: +1 212 479 6000 Facsimile: +1 212 479 6275 Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement. If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☐ If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐ If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐ If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

☐ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933. Emerging growth company ☒ If an emerging growth company that prepares its financial statements in accordance with U.S.

GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐ † The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Proposed maximum aggregate offering price(3)(4) Amount of registration fee(5) Ordinary Shares, nominal value £0.01 per share(1)(2) $115,000,000 $13,328.50 (1) These ordinary shares are represented by American Depositary Shares, or ADSs, each of which represents ordinary shares of the registrant. (2) ADSs issuable on deposit of the ordinary shares registered hereby will be registered pursuant to a separate registration statement on Form F-6 (File No.: 333- ).

(3) Estimated solely for the purpose of determining the amount of the registration fee in accordance with Rule 457(o) of the Securities Act of 1933, as amended. (4) Includes the aggregate offering price of additional ordinary shares represented by ADSs that the underwriters may purchase pursuant to an option to purchase additional shares solely to cover over-allotments, if any. (5) Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price. The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Commission, acting pursuant to such Section 8(a), may determine. The information in this preliminary prospectus is not complete and may be changed.

We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. SUBJECT TO COMPLETION, DATED SEPTEMBER 1, 2017 PRELIMINARY PROSPECTUS American Depositary Shares Representing Ordinary Shares $ per American Depositary Share This is the initial public offering of our American Depositary Shares, or ADSs. We are selling of our ADSs in this offering. Each ADS will represent ordinary shares, nominal value £0.01 per share.

The ADSs may be evidenced by American Depositary Receipts, or ADRs. We expect that the initial public offering price will be between $ and $ per ADS. No public market has previously existed for our ADSs or ordinary shares. We have applied to list the ADSs on the Nasdaq Global Market under the symbol “NCNA.” We are an “emerging growth company” as such term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company reporting requirements.

Investing in our ADSs involves a high degree of risk. See “” beginning on page 11. Neither the U.S. Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. Per ADS Total Public Offering Price $ $ Underwriting Discounts and Commissions 1 $ $ Proceeds to NuCana (before expenses) $ $ (1) We refer you to “Underwriting” beginning on page 188 for additional information regarding underwriting compensation.

The underwriters have an option to purchase up to additional ADSs from us at the public offering price, less the underwriting discounts and commissions payable by us, for 30 days after the date of this prospectus to cover over-allotments, if any. Delivery of the ADSs will be made against payment in New York, New York on or about, 2017.

Joint Book-Running Managers Citigroup Jefferies Cowen Co-Manager William Blair, 2017 You should rely only on the information contained in this prospectus and any related free-writing prospectus that we authorize to be distributed to you. We have not, and the underwriters have not, authorized any person to provide you with information different from that contained in this prospectus or any related free-writing prospectus that we authorize to be distributed to you.

This prospectus is not an offer to sell, nor is it seeking an offer to buy, these securities in any jurisdiction where the offer or sale is not permitted. The information in this prospectus speaks only as of the date of this prospectus unless the information specifically indicates that another date applies, regardless of the time of delivery of this prospectus or of any sale of the securities offered hereby. TABLE OF CONTENTS Page ii ii 1 11 64 65 66 67 68 70 72 73 88 132 143 145 147 166 177 179 188 194 195 195 195 195 F-1 No action is being taken in any jurisdiction outside the United States to permit a public offering of the ADSs or possession or distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of the prospectus applicable to that jurisdiction. We are incorporated under the laws of England and Wales and a majority of our outstanding securities are owned by non-U.S.

Under the rules of the U.S. Securities and Exchange Commission, or the SEC, we are currently eligible for treatment as a “foreign private issuer.” As a foreign private issuer, we will not be required to file periodic reports and financial statements with the SEC as frequently or as promptly as domestic registrants whose securities are registered under the Securities Exchange Act of 1934, as amended. I ABOUT THIS PROSPECTUS On August 29, 2017, we re-registered NuCana BioMed Limited as a public limited company and changed our name from NuCana BioMed Limited to NuCana plc. Unless otherwise indicated or the context otherwise requires, in this prospectus, “NuCana,” “NuCana BioMed Limited,” “NuCana plc,” the “Group,” the “company,” “we,” “us” and “our” refer to (i) NuCana BioMed Limited and its consolidated subsidiaries prior to the re-registration of NuCana BioMed Limited as a public limited company and (ii) NuCana plc and its consolidated subsidiaries after the re-registration of NuCana BioMed Limited as a public limited company.

See “Description of Share Capital.” PRESENTATION OF FINANCIAL INFORMATION We report under International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB. None of the financial statements were prepared in accordance with generally accepted accounting principles in the United States.

We present our financial statements in pounds sterling and in accordance with IFRS. All references in this prospectus to “$” are to U.S. Dollars and all references to “£” are to pounds sterling. Unless otherwise indicated, certain U.S.

Dollar amounts contained in this prospectus have been translated into pounds sterling at the rate on June 30, 2017 of £1.00 to $1.2995. These translations should not be considered representations that any such amounts have been, could have been or could be converted into pounds sterling at that or any other exchange rate as of that or any other date. We have made rounding adjustments to some of the figures included in this prospectus. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that preceded them. SUMMARY   This summary highlights information contained elsewhere in this prospectus. It may not contain all of the information that may be important to you. Before investing in our ADSs, you should read this entire prospectus carefully for a more complete understanding of our business and this offering, including our consolidated financial statements and the notes thereto, and the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in this prospectus.

Overview   We are a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide ™ technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Our most advanced ProTide candidates, Acelarin ® and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical trials across several solid tumor indications, including ovarian cancer, biliary cancer and pancreatic cancer. NUC-3373 is currently in a Phase 1 trial for the potential treatment of a wide range of advanced solid tumor cancers. We have retained worldwide rights to these lead product candidates as well as our preclinical product candidates, all of which we refer to as ProTides.

Acelarin, our most advanced product candidate, is a potential first-in-class ProTide that has been evaluated in over 130 patients. Acelarin is a ProTide transformation of gemcitabine that we believe could replace gemcitabine in certain cancer indications and have utility across a range of other cancers. In a Phase 1 dose-ranging trial in 49 evaluable patients with advanced metastatic solid tumors, Acelarin was well tolerated, achieved a high disease control rate and was associated with intracellular levels of active anti-cancer metabolite over 200 times higher than those reported for gemcitabine. A subset of 14 evaluable patients with relapsed/refractory gynecological cancers achieved a high disease control rate.

In a Phase 1b dose-ranging trial in 23 evaluable patients with recurrent ovarian cancer, Acelarin was combined with carboplatin and achieved a high disease control rate. As these results were obtained in first-in-human dose-ranging trials, they are not suitable for marketing approval. However, based on the encouraging disease control rates and the tolerability profile, we have begun a Phase 2 trial of Acelarin in patients with platinum-resistant ovarian cancer, for which we expect to report interim data in 2018. Acelarin is also being evaluated in another Phase 1b trial in patients with biliary cancer to determine its optimal dose in combination with cisplatin. We expect to report data from this trial in 2018, after which we plan to commence a multi-national Phase 3 trial. In addition, the National Cancer Research Institute in the United Kingdom is facilitating a Phase 3 trial of Acelarin for the treatment of patients with pancreatic cancer. NUC-3373, our second product candidate, is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, or 5-FU, which we believe has the potential to replace 5-FU as the standard of care in the treatment of a wide range of cancers.

In preclinical studies, we observed that NUC-3373 overcame the key resistance mechanisms associated with 5-FU and generated intracellular levels of active anti-cancer metabolite over 300 times higher than that of 5-FU. NUC-3373 is currently being evaluated in a Phase 1 clinical trial of patients with advanced solid tumors and we expect to report interim data from this trial in the second half of 2017. Contingent on regulatory guidance and other factors, we plan to initiate a number of clinical trials in 2018: a Phase 1b trial of NUC-3373 in patients with colorectal cancer together with other agents routinely used in 5-FU combination regimens; a Phase 3 trial in patients with advanced colorectal cancer; and a Phase 2 trial in patients with advanced breast cancer. NUC-7738, our third product candidate, is a ProTide transformation of cordycepin, a novel nucleoside analog that has shown potent anti-cancer activity in preclinical studies.

We are evaluating NUC-7738 in preclinical studies and we expect to initiate a Phase 1 clinical trial in 2018. Despite the widespread use of nucleoside analogs, their efficacy is severely limited by cancer cell resistance mechanisms and they are often poorly tolerated. Harnessing the power of phosphoramidate chemistry, we convert nucleoside analogs into activated nucleotide analogs with the addition of a phosphate group, which is protected by specific combinations of aryl, ester and amino acid groupings. By adding and protecting this phosphate group, we design our ProTides to avoid or overcome key cancer resistance mechanisms in the uptake, activation and breakdown of nucleoside analogs. As a result, we believe our ProTides have the potential to generate hundreds of times higher concentrations of the active anti-cancer metabolites inside tumor cells, potentially making our ProTides more effective than the current standards of care. Because our ProTides resist breakdown, and are thus more stable, we believe they are also able to reduce or eliminate the generation of toxic byproducts that can result from the breakdown of nucleoside analogs like gemcitabine and 5-FU.

Our proprietary ProTide technology was invented in the Cardiff University laboratory of our late Chief Scientific Officer, Professor Christopher McGuigan, who conceived of, and filed the original composition of matter patents for our initial ProTides. The unique feature of his discovery was the specific combination of aryl, ester and amino acid groupings that protect the activated, or phosphorylated, nucleoside analog.

This phosphoramidate chemistry approach is the key to the ProTide technology. Every ProTide grouping is distinct, and Professor McGuigan and his team synthesized and tested thousands of compounds in order to identify the optimal ProTide grouping for each underlying nucleoside analog. We have licensed what we believe to be the foundational patent estate for the application of phosphoramidate chemistry in oncology. We have granted patents in key markets, including the United States, Europe and Japan, protecting the composition of matter of Acelarin, NUC-3373 and other of our product candidates. Professor McGuigan’s work preceded and helped lead to the development of several FDA-approved anti-viral drugs containing nucleotide analogs, including: sofosbuvir, or Sovaldi ®, which is also a key component of Harvoni ®; and tenofovir alafenamide fumarate, or TAF, which is a key component of Genvoya ®, Descovy ® and Odefsey ®.

We are led by Hugh S. Griffith, our founder and Chief Executive Officer, who brings over 25 years of experience in the biopharmaceutical industry, including at Abbott Laboratories (now AbbVie Inc.) and Parke-Davis Warner Lambert (now Pfizer Inc.). Before founding NuCana, he led the operations of Bioenvision, Inc. From start-up through its acquisition by Genzyme Corporation. While at Bioenvision, he was instrumental in developing and commercializing clofarabine, a nucleoside analog for the treatment of pediatric leukemia. We are backed by leading life sciences investors, including Sofinnova Partners, Sofinnova Ventures, Morningside Group and Scottish Enterprise. Our Strategy   Our goal is to transform standards of care and improve survival for patients across a wide range of cancer indications.

Our strategy includes the following key components:     •   Rapidly develop Acelarin as a first-in-class nucleotide analog for the treatment of patients with cancer. We believe that Acelarin has the potential to replace the core chemotherapy component of treatment regimens for patients with various cancers, including:     •   Platinum-resistant ovarian cancer. We expect to report data from a Phase 2 trial of Acelarin in 2018. We also intend to explore the use of Acelarin in combination with Avastin, a widely used agent in the treatment of several cancers, and expect to report data from this trial in 2018. •   Platinum-sensitive ovarian cancer.

We expect to report data from a Phase 1b trial of Acelarin in combination with carboplatin during the second half of 2017. Contingent on regulatory guidance and other factors, we expect to commence a Phase 3 trial of Acelarin in combination with carboplatin for this indication in 2018. •   Biliary cancer. We expect to report data from a Phase 1b trial of Acelarin in combination with cisplatin in 2018. Contingent on regulatory guidance and other factors, we plan to commence a Phase 3 trial of Acelarin in combination with cisplatin as a first-line treatment in 2018. •   Pancreatic cancer.

The National Cancer Research Institute in the United Kingdom is facilitating a Phase 3 trial of Acelarin as a first-line treatment compared to gemcitabine. •   Rapidly develop NUC-3373 to replace 5-FU as the standard of care for the treatment of patients with various cancers. •   Advanced solid tumors.

We expect interim data from a Phase 1 trial of NUC-3373 in patients with advanced solid tumors in the second half of 2017. We expect to report final data from this trial in 2018. •   Colorectal cancer. We plan to establish the optimal dose of NUC-3373 in combination with other agents in a Phase 1b trial in 2018. Contingent on regulatory guidance and other factors, we also intend to initiate a Phase 3 trial of NUC-3373 monotherapy in 2018.

•   Breast cancer. We intend to conduct a Phase 2 trial of NUC-3373 compared to capecitabine, the oral version of 5-FU, in patients with recurrent breast cancer and anticipate reporting interim data from this trial in 2018. •   Rapidly advance NUC-7738 into clinical trials. NUC-7738, a ProTide based on a novel nucleoside analog, is currently undergoing preclinical studies and we expect to initiate a Phase 1 trial in 2018 for solid tumors. In addition, we plan to develop NUC-7738 for the treatment of hematological malignancies. •   Leverage our proprietary ProTide technology platform to develop additional product candidates.

We are pursuing both the transformation of well-established and widely used nucleoside analogs as well as novel nucleoside analogs, which we believe have the potential to address additional areas of unmet medical need in oncology. •   Continue to strengthen our intellectual property position. We own or have exclusive rights to the core technologies underlying our ProTide technology platform. We have granted patents in key markets, including the United States, Europe and Japan, protecting the composition of matter of Acelarin, NUC-3373 and other of our product candidates. We intend to further expand and enhance our intellectual property position.

•   Build a focused commercial organization. We have worldwide rights to all product candidates that we are developing. We believe that many of the cancers we are initially targeting with our ProTides can be addressed by a focused sales and marketing team. We plan to commercialize any product candidates for which we receive regulatory marketing approval using a specialized sales force in the United States and Europe.

Our Pipeline   We take a scientifically driven approach to designing ProTides, which we believe have the potential to result in highly efficacious cancer therapies with improved tolerability. Our pipeline of product candidates is summarized below. Corporate Information   NuCana was incorporated under the laws of England and Wales in 1997 under the name Biomed (UK) Limited, and commenced operations in 2008.

On April 28, 2008, we changed our name to NuCana BioMed Limited. On August 29, 2017, we re-registered as a public limited company and changed our name to NuCana plc. Our registered office is 77/78 Cannon Street, London EC4N 6AF, United Kingdom. Our principal executive offices are located at 10 Lochside Place, Edinburgh, EH12 9RG, United Kingdom, our general telephone number is +44 (0)131 248 3660 and our internet address is Our website and the information contained on or accessible through our website are not part of this prospectus. NuCana, the NuCana logo and other trademarks or service marks of NuCana plc appearing in this prospectus are the property of NuCana plc. Trade names, trademarks and service marks of other companies appearing in this prospectus are the property of their respective owners.

Solely for convenience, the trademarks, service marks and trade names referred to in this prospectus may be without the ® and ™ symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights to these trademarks, service marks and trade names. Risk Factors   Our business is subject to numerous risks that could prevent us from successfully implementing our business strategy. These and other risks are discussed more fully in “Risk Factors” immediately following this prospectus summary and include the following:     •   We have incurred significant operating losses since our inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability. •   We depend heavily on the success of our product candidates, Acelarin, NUC-3373 and NUC-7738.

We cannot give any assurance that these product candidates will receive regulatory approval for any indication, which is necessary before any of them can be commercialized. •   Our lack of any approved products and our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability. •   We will require substantial additional funding, which may not be available to us on acceptable terms, or at all. •   Drug development involves a lengthy and expensive process, with an uncertain outcome.

We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development, and may experience delays in obtaining, or ultimately be unable to obtain, the approval, of our product candidates. •   Initial success in early-stage clinical trials may not be indicative of results obtained in later-stage trials, and the results of our clinical trials may not meet the level of statistical significance required by the Food and Drug Administration, or FDA, or comparable foreign regulatory authorities for marketing approval. In addition, the data from the Phase 1b trial are interim and may change as the data are further examined, more patient data become available and the final clinical study report is prepared and issued.

•   We may not be successful in our efforts to use and expand our technology platform to build a pipeline of additional ProTide candidates. •   Our product candidates may cause undesirable side effects that could delay or prevent their marketing approval, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if any. •   We rely on, and expect to continue to rely on, third parties to conduct our clinical trials for our product candidates.

•   We contract with third parties for the manufacture and shipment of our product candidates for preclinical studies and clinical trials and expect to continue to do so for commercialization. •   We have entered into, and may in the future enter into, collaborations with third parties to discover or develop product candidates. If these collaborations are not successful, our business could be adversely affected. •   We face substantial competition, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.

•   If we are unable to obtain and maintain intellectual property protection for our technology and products, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired. In addition, if we infringe the valid patent rights of others, we may be prevented from making, using or selling our products or may be subject to damages or penalties. •   We currently have a limited number of employees, and our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.

Implications of Being an Emerging Growth Company and a Foreign Private Issuer   We qualify as an “emerging growth company,” or EGC, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As such, we may take advantage of specified reduced reporting requirements and are relieved of certain other significant requirements that are otherwise generally applicable to public companies in the United States. These provisions include:     •   the ability to include only two years of audited financial statements and only two years of related Management’s Discussion and Analysis of Financial Condition and Results of Operations disclosure; and     •   an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002. We may take advantage of these provisions for up to five years or such earlier time that we are no longer an EGC. We would cease to be an EGC if we have more than $1.07 billion in total annual gross revenue, have more than $700 million in market value of our ordinary shares held by non-affiliates or issue more than $1.0 billion of non-convertible debt over a three-year period. Upon the completion of this offering, we will report under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as a non-U.S. Company with foreign private issuer status.

Even if we no longer qualify as an EGC, as long as we qualify as a foreign private issuer under the Exchange Act we will be exempt from certain provisions of the Exchange Act that are applicable to U.S. THE OFFERING   ADSs offered by us          ADSs, each representing              ordinary shares. Over-allotment option We have granted the underwriters an option for a period of 30 days from the date of this prospectus to purchase up to             additional ADSs from us to cover over-allotments, if any. Ordinary shares to be outstanding immediately after this offering          ordinary shares (or              ordinary shares if the underwriters exercise in full their over-allotment option to purchase an additional              ADSs). American Depositary Shares Each ADS represents              ordinary shares, nominal value £0.01 per share.

The depositary or its custodian, or a nominee of either, will hold the ordinary shares underlying your ADSs. As an ADS holder you will not be treated as one of our shareholders and you will not have shareholder rights. You will have rights as provided in the deposit agreement. You may cancel your ADSs and withdraw the underlying ordinary shares as provided in the deposit agreement. We may amend or terminate the deposit agreement without your consent.

If you continue to hold your ADSs following an amendment, you agree to be bound by the terms of the deposit agreement then in effect. To better understand the terms of the ADSs, you should carefully read “Description of American Depositary Shares” in this prospectus. You should also read the deposit agreement, which is an exhibit to the registration statement that includes this prospectus. Depositary Citibank, N.A. Shareholder approval of offering Under English law, certain steps necessary for the completion of this offering require the approval of our shareholders by way of ordinary resolutions approved by more than 50% of all voting rights and special resolutions approved by at least 75% of all voting rights. We will receive all such required approvals prior to the completion of this offering.

See “Description of Share Capital” in this prospectus. Use of proceeds We expect to receive total estimated net proceeds from this offering of approximately $            million, assuming an initial public offering price of $             per ADS, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds of this offering, together with our existing cash and cash equivalents, to fund our planned development of Acelarin, NUC-3373 and NUC-7738, other research and development activities and for working capital and other general corporate purposes. See “Use of Proceeds” in this prospectus. Risk factors You should carefully read the information set forth under “Risk Factors” beginning on page 11 of this prospectus before investing in our ADSs.

SUMMARY CONSOLIDATED FINANCIAL DATA   The following tables summarize our consolidated financial data as of the dates and for the periods indicated. The consolidated financial data as of and for the years ended December 31, 2015 and 2016 have been derived from our consolidated financial statements, which have been prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standard Board, or IASB, and audited in accordance with the standards of the Public Company Accounting Oversight Board (United States), and included elsewhere in this prospectus. The consolidated financial data as of and for the six months ended June 30, 2016 and 2017 have been derived from our unaudited consolidated interim financial statements included elsewhere in this prospectus.

The unaudited consolidated interim financial statements have been prepared on the same basis as our audited consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, that we consider necessary for a fair statement of our financial position and operating results as of the dates and for the periods presented. Our historical results are not necessarily indicative of the results that may be expected in the future and our results for the six months ended June 30, 2017 are not necessarily indicative of our results to be expected for the full year 2017. The following summary consolidated financial data should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements included elsewhere in this prospectus.